Asensus Surgical — TransEnterix — H.C. Wainwright 22nd Annual Global Investment Conference (September 2020)
20 slides from Asensus Surgical's conference presentation, Sep 15, 2020

Slide 1: H.C. Wainwright 22nd Annual Global Investment Conference
= eenente H.C. Wainwright 22nd Annual Global nvestment Conference ithony Fernando, President & CEO = September 15, 2020

Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Wransenterix This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the me

Slide 3: Our Strategic Intent
Wransenterix | OUR STRATEGIC INTENT At TransEnterix, we believe in digitizing the interface between the surgeon and patient in laparoscopy to increase control and reduce surgical variability for improved patient outcomes in today’s value-based healthcare environment.

Slide 4: Company Overview
WransEnterix COMPANY OVERVIEW

Slide 5: Early-commercial stage company ushering in a new era of minimally invasive surgery
EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERAOF | TRANSENTERIX (NYSE American:TRXC) Wransenterix MINIMALLY INVASIVE SURGERY Senhance Surgical Robotic System — the first and only Digital Laparoscopy platform 7 Significant and differentiated addressable market Senhance opportunity FDA Cleared,

Slide 6: Company Snapshot
COMPANY SNAPSHOT Wransenterix FIRST NEW ENTRANT IN THE FIELD OF ABDOMINAL SURGICAL ROBOTICS IN NEARLY 20 YEARS Active sites in the ieremmgarve Igutummnreene _ gareeocuscmerccuncecome U.S., E.U. and Asia 3,400+ Surgeries Performed, to date ‘Transenterix Japan Toaye jue coe Taiwan Ch 140 global employ

Slide 7: Global Trends in Robotic Surgery
GLOBAL TRENDS IN ROBOTIC SURGERY Wransenterix SURGICAL ROBOTICS IS ALARGE AND FAST GROWING MARKET AND LAPAROSCOPIC SURGERY ISA GREENFIELD OPPORTUNITY ~$16B A The abdominal robotic ‘surgery market is projected to grow at a double digit CAGR over the foreseeable future ~$3.7B 2018 2023 10mm Annual Abd

Slide 8: Improve Outcomes, Efficiencies, and Talent Retention
IMPROVE OUTCOMES, EFFICIENCIES, AND TALENT RETENTION THE PRESSURE AND IMPACT ON SURGEONS ARE INCREASING UNDER [ VALUE-BASED HEALTHCARE IS FORCING HOSPITALS TO SS THE CONSTRAINTS OF VALUE-BASED HEALTHCARE Laparoscopy is the most widely performed surgical technique and carries limitations that compoun

Slide 9: The Senhance Surgical System
WransEnterix The Senhance Surgical System

Slide 10: Senhance System Addresses Key Challenges Facing Hospitals and Laparoscopic Surgeons
FACING HOSPITALS AND LAPAROSCOPIC SURGEONS [ SENHANCE SYSTEM ADDRESSES KEY CHALLENGES SF SAcenterie BUILDING THE BRIDGE FROM LAPAROSCOPY TO ROBOTICS First robotic system with ‘Augmented Intelligence (Al) ‘and Machine Vision g ‘ Capabilties > Senhance First robotic system 10 offer the security of hap

Slide 11: We Are Uniquely Focused on Digital Laparoscopy
WE ARE UNIQUELY FOCUSED ON DIGITAL LAPAROSCOPY >Vfransenterix: AN OPPORTUNITY AND NEED TO ADD TO THE WAYS SURGICAL ROBOTICS CREATES VALUE Wransenteric INTUITIVE Senhance Da Vinci Feature Implication Feature Implication Motion = Lap = Fully reusable = Limited Use (10x max) Instruments = 5mm and 3mm +

Slide 12: Our Plan for 2020
WransEnterix Our Plan for 2020

Slide 13: 2020 — Senhance and Digital Laparoscopy
2020 — SENHANCE AND DIGITAL LAPAROSCOPY ; RECOGNIZED AS KEY COMPONENTS FOR ROBOTIC GROWTHT™="s=nver'= WEARE FOCUSED ON + Expand the number of sites using | Publication of evidence supporting | = Scene cognition and Augmented the Senhance System in key Senhance value propositions Inteligence technolo

Slide 14: Strong, Broad-Based Clinical Performance
STRONG, BROAD-BASED CLINICAL PERFORMANCE SENHANCE DEMONSTRATING STRONG CLINICAL PERFORMANCE ACROSS THE THREE MAJOR GEOGRAPHIES Wrensenterix GLOBAL CLINICAL CASE VOLUME TREND 2019/2020 CASE MIX ROW MUS Asia Gynecology 1,612 iy _ Colorectal 11% * TransEnerix Estimates ang YTD Actual

Slide 15: The First Machine Vision System in Robotic Surgery
THE FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY Wransenterix LEADING THE WAY IN AUGMENTED INTELLIGENCE AND MACHINE VISION IN SURGERY SENHANCE INTELLIGENT SURGICAL UNIT (ISU) >! FDAS10(k) Approved In Clinical use in in March 2020 the US 3D POINT TO POINT CRITICAL STRUCTURE DEFECT IDENTIFICATION AN

Slide 16: General Surgery Opportunity in the U.S.
GENERAL SURGERY OPPORTUNITY IN THE U.S. SS ee GROWTH IN GENERAL SURGERY MUST COME FROM LAPAROSCOPIC. MIS PROCEDURES US Laparoscopic Procedures by Type = Based on current Senhance FDA 510(k) aeentectomy approval, 1.4M procedures are addressable in the US Bariatric FDA Review * In-Process . 7 - * Appr

Slide 17: Financial Overview & Key Operational Accomplishments
WransEnterix Financial Overview & Key Operational Accomplishments

Slide 18: 2020 Operational Highlights
2020 OPERATIONAL HIGHLIGHTS VWransenterix SIGNIFICANT OPERATIONAL PROGRESS YEAR TO DATE Eight Senhance lease agreements signed, 6 clinical programs initiated and completed ~900 cases YTD Filed and received FDA clearance for Augmented Intelligence(Al) and machine vision system, Intelligent Surgical U

Slide 19: Financial Highlights
FINANCIAL HIGHLIGHTS Wransenterix PRUDENTLY MANAGING CASH TO FUND EXECUTION Pro-forma cash of $29.9M' \ Debt-free, except for government promissory note Zz Completed restructuring expected to reduce cash burn by 37% in FY2020 compared to FY2019 l Reduced operating expenses by 15% or $2.4M in Q2 2020

Slide 20: = acErcerie
= acErcerie
Source: SEC EDGAR · 8-K filed Sep 15, 2020
More decks from Asensus Surgical Inc
Investor Presentation (June 2023)25 slides · Jun 5, 2023
Investor Day (February 2023)65 slides · Feb 21, 2023
40th Annual J.P. Morgan Healthcare Conference (January 2022)23 slides · Jan 13, 2022
Transenterix — Investor Day (February 2021)22 slides · Feb 23, 2021
TransEnterix — Q3 2019 Earnings Presentation25 slides · Nov 13, 2019
Transenterix — JP Morgan Healthcare Conference 201822 slides · Jan 8, 2018